Odyssey Thera Expands Pfizer Drug-Discovery Deal

Odyssey Thera said last week that it has expanded its agreement with Pfizer to profile compounds using Odyssey's panel of cell-based assays in order to characterize mechanism of action and pathway activity in human cells.

The project will focus on 500 compounds from multiple therapeutic areas, Odyssey said.

Odyssey Thera's cell-based drug-discovery platform is based on its patented protein-fragment complementation assay.

The companies began their collaboration in November 2003.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.